IC
SPRB

Ikarian Capital’s Spruce Biosciences SPRB Stock Holding History

Ikarian Capital’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.55M Hold
121,356
– – 0.71% 39
2026
Q1 		$7.93M Hold
121,356
– – 0.64% 45
2025
Q4 		$10.6M Buy
121,356
+108,024
+810% +$11.6M 0.83% 34
2025
Q3 		$119K Sell
13,332
-1
-0% -$9 0.01% 161
2025
Q2 		$72.5K Hold
13,333
– – 0.01% 125
2025
Q1 		$290K Hold
13,333
– – 0.04% 131
2024
Q4 		$420K Buy
+13,333
New +$489K 0.06% 133

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Ikarian Capital's SPRB Position: Q2 2026 in Review

Ikarian Capital held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 121,356 shares worth $6.55M. The position accounts for 0.71% of the portfolio, ranked #39.

Ikarian Capital first reported a position in SPRB in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.6M in Q4 2025. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Ikarian Capital held 121,356 shares of Spruce Biosciences worth $6.55M as of Q2 2026.
  • Ikarian Capital left its Spruce Biosciences share count unchanged in Q2 2026.
  • Spruce Biosciences made up 0.71% of Ikarian Capital's portfolio in Q2 2026, its #39 holding.
  • Ikarian Capital first reported a position in Spruce Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Ikarian Capital's Spruce Biosciences position peaked at $10.6M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.